No business profile yet.
Size Australian Unity Ltd Pref (AYUPA.AX) is an Australia Health Care company (Medical/Nursing Services) with a market value of $352M, the 296th largest of 317 Australia companies the cockpit tracks. Shares closed at A$68.96 on 18 Nov 2026.
Performance Over six months the shares gained 17.2%, against -4.0% for the median peer and +1.2% for the Australia market (cap-weighted) — 3rd highest of 20 in its peer set.
Growth Revenue was unchanged over the last twelve months (peer median +6.0%); the operating margin is -2.3% (peer median 8.4%).
Valuation It trades at 0.42× book value against a peer median of 1.60× (cheapest of 20).
Price implies The share price implies a return on equity of about 4.7%; Australian Unity Ltd Pref delivers -12.4%, so the price asks more than the business earns today.
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|---|
| Revenue | A$2.53B | A$2.53B | A$2.53B | A$2.04B | A$1.78B |
| Revenue growth | — | 0% | +24% | +15% | — |
| Net income | -A$160M | -A$160M | A$29.3M | -A$24.0M | A$56.8M |
| Free cash flow | A$170M | A$170M | A$46.8M | A$163M | A$2.46M |
| Capital expenditure | A$41.1M | A$41.1M | A$83.6M | A$43.5M | A$39.8M |
| Total debt | n/a | A$551M | A$674M | A$2.20B | A$1.80B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | AYUPA.AX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +11.2% | -9.6% | 4th highest of 21 |
| 6-month return | +17.2% | -4.0% | 3rd highest of 20 |
| Return on equity | -12.4% | 2.6% | 3rd lowest of 20 |
| Price / book | 0.42× | 1.60× | cheapest of 20 |
| ROE the price implies | 4.7% | 15.3% | least demanding of 20 |
| ROE delivered | -12.4% | 1.6% | 3rd lowest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | ROE | Price / book | Implied ROE | Delivered ROE |
|---|---|---|---|---|---|---|---|---|
| Australian Unity Ltd Pref AYUPA.AX | Australia | $352M | +17% | 0% | -12% | 0.42× | 4.7% | -12.4% |
| M1 Kliniken M12.DE | Germany | $368M | +1% | -28% | 17% | 3.02× | 14.4% | 16.7% |
| Tellgen 300642.SZ | China | $328M | -11% | +5% | 1% | 1.53× | 17.2% | 1.3% |
| Oncology Institute STLN | United States | $326M | n/a | +35% | n/a | n/a | n/a | n/a |
| NIOX NIOX.L | United Kingdom | $325M | +3% | +3% | 11% | 3.88× | 18.3% | 10.7% |
| ADICON 9860.HK | Hong Kong | $393M | +5% | +1% | 1% | 1.50× | 8.6% | 1.4% |
| Jeena Sikho Lifecare JSLL.NS | India | $394M | -55% | +135% | 49% | 7.12× | 73.5% | 49.2% |
| Auna AUNA | United States | $309M | -5% | +17% | 1% | 0.57× | 6.1% | 0.8% |
| Universal Vision Biotechnology 3218.TWO | Taiwan | $309M | -4% | +5% | 27% | 2.42× | 7.2% | 27.1% |
| Integral Diagnostics IDX.AX | Australia | $413M | -22% | +26% | 3% | 0.91× | 8.1% | 3.2% |
| Australian Clinical Labs ACL.AX | Australia | $418M | +68% | -1% | 15% | 4.14× | 36.7% | 14.8% |
| Dr. Agarwal'S Eye Hospital DRAGARWQ.NS | India | $292M | +14% | +20% | 25% | 8.14× | 73.3% | n/a |
| Strata Critical Medical SRTA | United States | $443M | -10% | +23% | -8% | 1.60× | 26.9% | -7.6% |
| JS Link 127120.KS | South Korea | $458M | -62% | +39% | -12% | 4.26× | 26.8% | -7.4% |
| Shanghai Labway Clinical Laboratory 301060.SZ | China | $518M | -17% | -19% | 3% | 2.20× | 15.3% | 2.6% |
| Ginkgo Bioworks DNA | United States | $547M | +9% | -44% | -54% | 1.32× | 17.3% | -53.6% |
| WELL Health Technologies WELL.TO | Canada | $661M | -9% | +29% | -16% | 1.19× | 11.5% | -15.7% |
| Fulgent Genetics FLGT | United States | $702M | +53% | +5% | -9% | 0.70× | 8.0% | -8.6% |
| Nephrocare Health Services NEPHROPLUS.NS | India | $702M | +1% | +33% | 9% | 5.52× | 56.8% | n/a |
| GMR Solutions GMRS | United States | $714M | -8% | -4% | 26% | 0.79× | 5.8% | n/a |
| Jinxin Fertility 1951.HK | Hong Kong | $758M | -4% | +7% | 2% | 0.57× | 8.5% | 1.9% |